Abstract
Objective
To analyse the factors related to the appearance, incidence and severity of toxicity associated with post-operative radiochemotherapy in rectal cancer.
Material and methods
Between January 1994 and September 1997, we prospectively collected the data on 122 patients treated for rectal adenocarcinoma in the B2-C stage. Surgery was followed by radiotherapy and chemotherapy (5-FU plus leucovorin) administered as an alternating, or as a concomitant, scheme. Pelvic volume was treated with a four-portal, or a two-portal, irradiation technique using megavoltage photon beams (60Co or 23 MV photons). Total administered dose was 50 Gy in 1.8–2 Gy fractions. Statistical analysis was performed to identify factors related to the incidence of toxicity, and its severity.
Results
Acute side effects were noted in 98 (80.3%) patients; the most frequent being diarrhea (55%) followed by skin reactions (40.1%). Toxicity occurred following the administration of a mean radiation dose of 26 Gy (range: 8–50 Gy). Grade 3 toxic events were observed in 20.5% of patients. It was necessary to interrupt treatment in 32.8% of patients for a mean period of 8.8 days. There were no grade 4 toxicities or therapy-related deaths. The concomitant scheme of radiochemotherapy (compared to alternating) was the main predictive factor for higher incidence (91.1% versus 74%; p=0.04), higher severity grade 3 (33.3% versus 13%; p=0.014) and early (following 22.7 Gy versus 28.4 Gy, p=0.012) acute toxicity.
With a median follow-up of 68.9 months, late grade 3 toxicity appeared in 13 patients (10.8%), and 10 patients (8.3%) required surgical treatment to resolve an intestinal obstruction. None of the parameters analysed influenced the late-onset toxicity, or the development of small-bowel obstruction.
Conclusions
In our study, the concomitant radiochemotherapy combination scheme was the main predictive factor for acute toxicity, but with no influence on late-onset toxicity. Our overall results were similar to others reported in the literature.
Resumen
|Objetivo
El propósito es estudiar la incidencia e intensidad de la toxicidad inherente al tratamiento radioquimioterápico postquirúrgico en cáncer rectal.
|Material y métodos
Se recogieron prospectivamente los datos de 122 pacientes tratados con intención radical entre enero de 1994 y septiembre de 1997 por un adenocarcinoma rectal en estadio B2-C. La cirugía fue seguida de radio y quimioterapia (5-FU en bolus y leucovorín), administradas siguiendo un esquema alternante o concomitante. El volumen pélvico fue tratado con técnica de dos o cuatro campos hasta una dosis total de 50 Gy (1,8–2 Gy/sesión) mediante fotones de Co-60 o Rx de 23 MV. Se ha realizado un análisis estadístico para la detección de los factores relacionados con la incidencia e intensidad de la toxicidad aparecida.
|Resultados
El 80,3% de los pacientes presentaron efectos agudos, siendo el más frecuente la aparición de diarrea (55%), seguido de epidermitis (40,1%). La toxicidad apareció tras una dosis media de radioterapia de 26 Gy (amplitud 8–50 Gy). Un 20,5% de los casos presentaron toxicidad grado 3. Fue necesario interrumpir temporalmente el tratamiento en un 32,8% de los pacientes (media: 8,8 días). No hubo ningún caso de toxicidad grado 4, ni muertes atribuibles al tratamiento combinado. La secuencia de combinación de radioquimioterapia fue el principal factor determinante de una mayor frecuencia (74% frente al 91,1%, p=0,04), mayor intensidad (13% frente al 33,3%, p=0,014) y más precocidad (tras 28,4 Gy frente a 22,7 Gy, p=0,012) de aparición de toxicidad aguda en el brazo de tratamiento concomitante.
Con una mediana de seguimiento de 68,9 meses. 13 pacientes (10,8%) presentaron toxicidad tardía grado 3, y 10 pacientes (8,3%) requirieron tratamiento quirúrgico para solucionar un cuadro obstructivo adherencial. Ningún parámetro analizado influyó en la aparición de toxicidad tardía de cualquier grado, o en el desarrollo de oclusión intestinal.
|Conclusiones
En nuestro estudio, el índice de toxicidad y su gravedad es similar a la recogida en la literatura, siendo la forma de combinación de la quimioterapia y radioterapia el principal factor predisponente a su aparición durante el tratamiento, pero sin influencia en la toxicidad tardía.
Similar content being viewed by others
References
National Institute of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444–9.
Glimelius B. Chemoradiotherapy for rectal cancer. Is there an optimal combination? Ann Oncol 2001;12(8):1039–45.
Minsky BD. Adjuvant therapy for rectal cancer. A good first step. N Engl J Med 1997;336(14):1016–7.
Bosset JF, Mantion G, Lorchel F, et al. Adjuvant and neoadjuvant radiation therapy for rectal cancer. Semin Oncol 2000;27(5 Suppl):60–5.
Minsky BD. Adjuvant radiation therapy for rectal cancer: is there finally an answer? Lancet 2001;358:1285–6.
Ooi BS, Tjandra JJ, Green MD. Morbidities of adjuvant chemotherapy and radiotherapy for resectable rectal cancer: an overview. Dis Colon Rectum 1999;42(3):403–18.
Astler VB, Coller FA. The prognostic significance of direct extension of carcinoma of the colon and rectum. Ann Surg 1954;139:846–52.
Rubin P. Special issue: Late effects of normal tissues consensus conference, including RTOG/EORTC SOMA scales. Int J Radiat Oncol Biol Phys 1995;31:1035–360.
Miñarro R, Black RJ, Martínez C, et al. Incidencia y mortalidad por cáncer en España. IARC Technical Report 2000;36:24–6.
Gunderson LL, Sosin H. Areas of failure found at reoperation (second or symptomatic look) following curative surgery for adenocarcinoma of the rectum: Clinicopathologic correlation and implications for adjuvant therapy. Cancer 1974;34:1278–92.
Rich T, Gunderson LL, Lew R, et al. Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 1983;52:1317–29.
Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med 1985;312:1465–72.
Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324:709–15.
Swedish rectal cancer trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997;336:980–7.
Valentini V, Coco C, Cellini N, et al. Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation. Int J Radiat Oncol Biol Phys 1999;45(5):1175–84.
Bosset JF, Magnin V, Maingon P, et al. Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial. Int J Radiat Oncol Biol Phys 2000; 46(2):323–7.
Grann A, Feng C, Wong D, et al. Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma. Int J Radiat Oncol Biol Phys 2001; 49(4):987–95.
Calvo FA, Gómez-Espí M, Díaz-González JA, et al. Pathologic downstaging of T3-4 Nx rectal cancer after chemoradiation: 5-fluorouracil vs. Tegafur. Int J Radiat Oncol Biol Phys 2001;51(5):1264–70.
Kapiteijn E, Marijnen AM, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorrectal excision for resectable rectal cancer. N Engl J Med 2001; 345:638–46.
Bosset JF, Horiot JC, Pavy JJ. Postoperative treatment of rectal cancer. In: Bleiberg H, Rougier P, Wilke HJ, editors. Management of colorectal cancer. London, UK: Martin Dunitz, 1998;p. 345–9.
León AI, López MP, Dorta FJ. Cáncer de colon y recto (II). Tratamiento de la enfermedad localizada. In: González Barón M, editor. Oncología Clínica. Patología especial. 2a ed. Madrid: McGraw-Hill/Interamericana, 1998; p.203–12.
Martenson JA, Urias R, Smalley SR, et al. Radiation therapy quality control in a clinical trial of adjuvant postoperative treatment for rectal cancer. Int J Radiat Oncol Biol Phys 1995;32(1):51–5.
Kollmorgen CF, Meagher AP, Wolff BG, et al. The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg 1994;220:676–82.
Perry MC, Eaton WL, Propert KJ, et al. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung. N Engl J Med 1987;316:912–8.
Pignon JP, Arriagada R, Idhe DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618–24.
Lupattelli M, Maranzano E, Bellavita R, et al. Adjuvant radiochemotherapy in high-risk rectal cancer results of prospective non-randomized study. Tumori 2001;87(4):239–47.
O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protacted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331:502–7.
Cabrera J, Montero MV, Muñoz JL, et al. Radioquimioterapia complementaria a cirugía radical en el adenocarcinoma de recto. Rev Oncol 2001;3:79–84.
Ooi BS, Tjandra JJ, Green MD. Morbidities of adjuvant chemotherapy and radiotherapy for resectable rectal cancer: an overview. Dis Colon Rectum 1999;42(3):403–18.
Bertuccelli M, Cartei F, Falcone A, et al. Postoperative adjuvant chemoradiotherapy for rectal cancer: analysis of acute and chronic toxicity. Tumori 1997;83(2):599–603.
Schild SE, Marterson JA Jr, Gunderson LL, et al. Postoperative adjuvant therapy of rectal cancer: An analysis of disease control, survival and prognostic factors. Int J Radiat Oncol Biol Phys 1989;17:55–62.
Buchanan R. Cobalt on the way out [letter]. Br Med J 1986;292:290.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Julve, J.V., Jaime, S.P., Orduña, V.A. et al. Adjuvant radiochemotherapy in rectal cancer: analysis of acute and late-onset toxicity. Rev Oncol 6, 150–158 (2004). https://doi.org/10.1007/BF02710116
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02710116